December 20, 202310:30 AM - 12:00 PM PT
Assessment of Needs
Substance use disorders, including stimulant use disorders, may disproportionately affect people with HIV. It is essential that clinicians who treat patients with HIV recognize the signs of stimulant use disorder and understand the current treatment options and challenges.
Drug Enforcement Agency certificate holders are now required to complete 8 hours of training on opioids, substance use disorders (SUDs), and pain management. The IAS–USA is excited to support you in meeting these new requirements with a free webinar series comprising 8 hours of training to help you provide the best possible care for your HIV patients! The fifth webinar in the series, presented by Steven J. Shoptaw, PhD, and moderated by Sandra A. Springer, MD, focuses on the role of stimulant use disorder on HIV-related morbidity and mortality and discusses the integration of contingency management and appropriate pharmacotherapies in HIV clinical settings.
On completion of this activity, learners will be able to:
- Describe the role of stimulant use disorder on HIV-related morbidity and mortality
- Make clinic changes to implement contingency management and medications as a tool to treat patients with stimulant use disorders
- List evidence-based therapies for harm reduction in patients with stimulant use disorder and HIV
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, December 20, 2023, 10:30 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at email@example.com or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Dr Shoptaw reported non-cash provision of medicines, equipment, or administrative support to his institution from Gilead Sciences, Inc, Indivior Inc, and Alkermes Inc; fees for participation in review activities, eg, data monitoring boards, statistical analysis, or endpoint adjudication committees, from Aelis Inc. (Updated October 10, 2023)
Dr Springer reported receiving consulting fees from Alkermes, Inc, and receiving in-kind study drug donations from Alkermes, Inc, and Indivior, Inc. (Updated October 25, 2023)
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated October 25, 2023)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated October 25, 2023)
The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.
These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.